Anxiety drug may help you with fear of social rejection

Image
ANI Washington D.C. [USA]
Last Updated : Jul 19 2017 | 2:42 PM IST

A team of researchers has found that low doses of anxiety disorder-reducing drug can help highly-anxious people overcome their fear of being over-looked and rejected socially.

According to researchers, low doses of anxiolytic drugs - such as diazepam (Valium) - can ameliorate (make something better) this effect by increasing the activity of mitochondria in the neurons of the brain pathway associated with motivation and reward.

Researchers from Carmen Sandi at École Polytechnique Federale de Lausanne in Switzerland showed that low doses of diazepam helps high-anxious rats overcome their social competition disadvantage.

Psychologists speak of anxiety in two forms - 'state' anxiety, which refers to anxiety arising from a particular situation; and 'trait' anxiety, which refers to anxiety as part of a person's overall personality.

'Trai' anxiety can undermine a person's confidence in competing for social standing, making them feel overlooked and rejected: a condition, which psychologists call social subordination.

Highly anxious individuals feel that they are in a circle of social disadvantage and more anxiety.

The scientists also found that it helped medium-anxious rats increase their ability to compete socially.

On the other hand, low-dose diazepam did not help low-anxious rats increase their already higher social competitiveness.

The team focused on two regions of the brain: First, the ventral tegmental area (VTA), which is one of the brain regions where diazepam is known to act. Second, the nucleus accumbens, which receives input from the VTA, which previously was shown to be heavily involved in trait anxiety and social competitiveness.

The scientists showed that diazepam increases the release of the neurotransmitter dopamine from VTA neurons to the nucleus accumbens.

The increased dopamine acts on specialised receptors on the nucleus accumbens neurons (D1 dopaminergic receptors), and activates them.

These in turn trigger a biochemical cascade that increases the activity and energy output of the neurons' mitochondria -- the cell's powerhouses.

The work establishes the role of anxiolytics in combating social subordination and, more critically, shows that mitochondrial function is a promising target for drug treatment of anxiety-related social dysfunctions.

The work is published in journal of Molecular Psychiatry.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 19 2017 | 2:42 PM IST

Next Story